Departed
Remy Gross
Director
SER ·
Serina Therapeutics, Inc.
The Company also announced the departure of Remy Gross from its Board of Directors effective May 22, 2025.
Ready 8-Ks
19
Latest filing
May 14, 2026 20:05 UTC
Top materiality
0.85
Event mix
other_material ×6 · earnings ×4 · regulatory ×4
Sentiment
6 pos · 4 neg · 9 neu
Latest earnings
reported 2026-Q1
Executive change
recent →
Recent 8-K filings for SER
Highest-materiality recent filing
Serina raises $15M first tranche (up to $30M) at $2.25/share (68% premium); Greg Bailey appointed Co-Chairman
- First tranche of $15M closed March 20, 2026; second tranche up to $15M due by April 30, 2026.
- Pricing at $2.25 per share (68% premium to March 17 close); 50% warrant coverage at $5 exercise (273% premium).
-
Serina Therapeutics Q1 2026 net loss $6.9M; Phase 1b study of SER-252 underway
Net loss of $6.9M ($0.58 per share) for Q1 2026 vs. $4.8M ($0.49) in Q1 2025.
-
Net loss $19.4M ($1.91/share) vs $11.1M ($1.51/share) in FY2024; operating expenses rose to $24.2M from $17.1M.
-
First tranche of $15M closed March 20, 2026; second tranche up to $15M due by April 30, 2026.
-
Serina Therapeutics receives FDA clearance for SER-252 IND in advanced Parkinson's
FDA cleared IND for SER-252, an investigational therapy for advanced Parkinson's disease.
-
Serina Therapeutics receives NYSE American deficiency notice for stockholders' equity below $2M
Stockholders' equity was $1.6M as of Sept 30, 2025, below $2M, $4M, and $6M thresholds.
-
Serina submits complete response to FDA clinical hold for SER-252 Parkinson's program
Complete response submitted Dec 9, 2025, addressing FDA's clinical hold on SER-252 related to trehalose excipient.
-
Serina Therapeutics Q3 net loss $4.6M; FDA places SER-252 on clinical hold
Net loss of $4.6M ($0.45 per share) vs net income of $1.4M in Q3 2024.
-
Serina Therapeutics announces FDA clinical hold on SER-252 IND for advanced Parkinson's disease
FDA placed clinical hold on SER-252 IND, requesting additional info on a commonly used excipient; not related to active drug or mechanism.
-
Serina Therapeutics draws first $5M tranche from $20M note for SER-252 Parkinson's trial
Received $5 million initial tranche under up to $20 million convertible note financing agreement.
-
Up to $20M drawn in 5 tranches tied to milestones for SER-252-1b registrational study; $5M available by Sept 30, 2025.
-
Serina Therapeutics Secures Up to $20M in Convertible Note for Parkinson's Trial
Unsecured convertible note up to $20M in five tranches tied to clinical milestones; first $5M available by Oct 1, 2025.
-
FDA Type B meeting written feedback supports advancing SER-252 (POZ-apomorphine) in registrational study.
-
Net loss $6.4M ($0.66/share) vs prior-year net income $5.2M ($0.61/share).
-
Serina appoints ex-Karuna CMO Brannan to board; director Gross departs
Appointed Dr. Stephen Brannan (former Karuna CMO) to board and Compensation Committee, effective May 22, 2025.
Executive changes
Appointed
Stephen Brannan
Director
SER ·
Serina Therapeutics, Inc.
On May 22, 2025 , the Board of Directors of Serina Therapeutics, Inc. (the “Company”) appointed Dr. Stephen Brannan to the Company’s Board of Directors, effective May 22, 2025.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.65 · Most common event other_material